To augment tumor assessments using AI-enabled solutions for clinical trials & cancer care
Qure.ai and Project Data Sphere, a nonprofit initiative of the CEO Roundtable on Cancer, have announced their partnership to augment tumor assessments using AI-enabled solutions for clinical trials and cancer care. The collaboration aims to increase efficiency and consistency in evaluating the effectiveness of cancer treatments, ultimately improving the quality of care for patients.
The focus of this collaboration is autoRECIST, a product of Project Data Sphere’s Images and Algorithms program. The program, initiated in consultation with the U.S. Food and Drug Administration, includes stakeholders and experts from across the pharmaceutical industry and academia. In collaboration with Qure.ai, autoRECIST will address the critical need for automating and standardising tumor response assessments in medical imaging to enhance cancer treatment and research. Rooted in current imaging guidelines, this AI clinical tool will aid radiologists in the detection, selection, measuring and tracking of lesions using defined criteria.
autoRECIST can improve clinical trials and cancer treatments through:
- Enhanced efficiency and improved accuracy through the automation of analyzing medical images (such as CT scans) and reducing variability when measuring tumor size and changes over time.
- Faster decision-making in the assessment of tumor response, which enables researchers and clinicians to quickly determine if a treatment is effective or if changes in care are required.
This collaboration enables the sharing of unique insights, advanced methodologies and access to a broader network of industry leaders, further enriching the development of the autoRECIST solution.
- Advertisement -